Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydroc...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Blackburn, Anthony C Shakya, Sagar Raj Carlos, Marlon Hadd, Mark A Castro, Ryan O Ma, You-An Rueter, Jaimie Karyn Selvey, Lee Alani Montalban, Antonio Garrido |
| description | The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of SlPi receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2023200978BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2023200978BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2023200978BB23</originalsourceid><addsrcrecordid>eNqNjT1OxDAQhdNQIOAOLigcKSMlzkoLJRuBKCgQPxVCK689YS15PdF4ImHOx8HYIA5A9b7ife-dVt8Dlyw2xpBQPYDlj5AWzDaKolHppxoM6DXoFbjiIk2YpEToQQuHMc7EdEDZl1jvMH2VSJ-lhq4xTd-sQFDY7otn-nVhke3b7j0kT8vG0bIOJThlXfB6oMNEc_JdrUZiNWdUIann7rFTjA4nIQabM7lgBb3yIRN75HxenYw2Zrz4y7Pq8u72ZbgHnGiLeTp-JJTtzatpTW_a9np9tdmY_p-1H5yaYHc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders</title><source>esp@cenet</source><creator>Blackburn, Anthony C ; Shakya, Sagar Raj ; Carlos, Marlon ; Hadd, Mark A ; Castro, Ryan O ; Ma, You-An ; Rueter, Jaimie Karyn ; Selvey, Lee Alani ; Montalban, Antonio Garrido</creator><creatorcontrib>Blackburn, Anthony C ; Shakya, Sagar Raj ; Carlos, Marlon ; Hadd, Mark A ; Castro, Ryan O ; Ma, You-An ; Rueter, Jaimie Karyn ; Selvey, Lee Alani ; Montalban, Antonio Garrido</creatorcontrib><description>The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of SlPi receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240725&DB=EPODOC&CC=AU&NR=2023200978B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240725&DB=EPODOC&CC=AU&NR=2023200978B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Blackburn, Anthony C</creatorcontrib><creatorcontrib>Shakya, Sagar Raj</creatorcontrib><creatorcontrib>Carlos, Marlon</creatorcontrib><creatorcontrib>Hadd, Mark A</creatorcontrib><creatorcontrib>Castro, Ryan O</creatorcontrib><creatorcontrib>Ma, You-An</creatorcontrib><creatorcontrib>Rueter, Jaimie Karyn</creatorcontrib><creatorcontrib>Selvey, Lee Alani</creatorcontrib><creatorcontrib>Montalban, Antonio Garrido</creatorcontrib><title>Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders</title><description>The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of SlPi receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjT1OxDAQhdNQIOAOLigcKSMlzkoLJRuBKCgQPxVCK689YS15PdF4ImHOx8HYIA5A9b7ife-dVt8Dlyw2xpBQPYDlj5AWzDaKolHppxoM6DXoFbjiIk2YpEToQQuHMc7EdEDZl1jvMH2VSJ-lhq4xTd-sQFDY7otn-nVhke3b7j0kT8vG0bIOJThlXfB6oMNEc_JdrUZiNWdUIann7rFTjA4nIQabM7lgBb3yIRN75HxenYw2Zrz4y7Pq8u72ZbgHnGiLeTp-JJTtzatpTW_a9np9tdmY_p-1H5yaYHc</recordid><startdate>20240725</startdate><enddate>20240725</enddate><creator>Blackburn, Anthony C</creator><creator>Shakya, Sagar Raj</creator><creator>Carlos, Marlon</creator><creator>Hadd, Mark A</creator><creator>Castro, Ryan O</creator><creator>Ma, You-An</creator><creator>Rueter, Jaimie Karyn</creator><creator>Selvey, Lee Alani</creator><creator>Montalban, Antonio Garrido</creator><scope>EVB</scope></search><sort><creationdate>20240725</creationdate><title>Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders</title><author>Blackburn, Anthony C ; Shakya, Sagar Raj ; Carlos, Marlon ; Hadd, Mark A ; Castro, Ryan O ; Ma, You-An ; Rueter, Jaimie Karyn ; Selvey, Lee Alani ; Montalban, Antonio Garrido</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2023200978BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Blackburn, Anthony C</creatorcontrib><creatorcontrib>Shakya, Sagar Raj</creatorcontrib><creatorcontrib>Carlos, Marlon</creatorcontrib><creatorcontrib>Hadd, Mark A</creatorcontrib><creatorcontrib>Castro, Ryan O</creatorcontrib><creatorcontrib>Ma, You-An</creatorcontrib><creatorcontrib>Rueter, Jaimie Karyn</creatorcontrib><creatorcontrib>Selvey, Lee Alani</creatorcontrib><creatorcontrib>Montalban, Antonio Garrido</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Blackburn, Anthony C</au><au>Shakya, Sagar Raj</au><au>Carlos, Marlon</au><au>Hadd, Mark A</au><au>Castro, Ryan O</au><au>Ma, You-An</au><au>Rueter, Jaimie Karyn</au><au>Selvey, Lee Alani</au><au>Montalban, Antonio Garrido</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders</title><date>2024-07-25</date><risdate>2024</risdate><abstract>The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of SlPi receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2023200978BB2 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A12%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Blackburn,%20Anthony%20C&rft.date=2024-07-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2023200978BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |